Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

ON-AIR 🟢 - Poo-tane Gas 50 min · 23 Sep 2026 · The Morning Rumble

Lemon LIVE at 5: Trump's Attack on the Media is an Attack on Democracy 57 min · 23 Sep 2026 · The Don Lemon Show

Iran's President Addresses the UN General Assembly 3 min · 23 Sep 2026 · Fox News Hourly Update

NPR News: 09-23-2026 6PM EDT 5 min · 23 Sep 2026 · NPR News Now

Matheson on Guerrero Jr.'s contract comments, his season performance and the optics of the statement 10 min · 23 Sep 2026 · OverDrive

H3 Tim Grunhard 39 min · 23 Sep 2026 · The Program

Report any issue

Source

Recorded23 Feb 2026

Publisheraudiomedica.com ↗

Handlerec:19315678

Show notes

Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in